About: Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 December 1996

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в грудні 1996 (uk) im Dezember 1996 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'avientu de 1996 (ast) scientific article published on 01 December 1996 (en)
publication date	wds:Q71876134-E8D05299-32B1-4016-98A8-D9EA1F121277
publication date	1996-12-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q71876134-AD8CEEC1-2A11-45C1-8F46-011E93ADAF36
language of work or name	English
author name string	wds:Q71876134-0DB1684A-EA97-4FBC-A201-F46517D5A1C0 wds:Q71876134-0F92168D-5F74-4A7B-B2C3-B2231ABAFAFC wds:Q71876134-27238007-AD60-430E-A1FB-7BB08D8436AB wds:Q71876134-68D65881-E888-4B31-B6AC-86C181078212 wds:Q71876134-6B9E02CC-1A70-46B8-865B-CDC2BD1EC167 wds:Q71876134-BCB95AFF-03CB-41B4-9F5B-3CAF143FF1BA wds:Q71876134-C38ED1A8-B282-4918-A8B4-30F91A07F437 wds:Q71876134-CCEFA5DA-C9FE-428D-AB44-2071B4617FB7 wds:Q71876134-D74D49A3-02C9-4235-9612-FCC708E0A896 wds:Q71876134-F281F34E-467A-435D-A7E5-A7915DD6783A
author name string	J Leslie J R Hebel C T Bever H S Panitch K P Johnson S Dhib-Jalbut O A Khan E Katz P A Anderson K L Conway
rdfs:label	Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial (en) Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial (nl)
skos:prefLabel	Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial (en) Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial (nl)
name	Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial (en) Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial (nl)
author	wds:Q71876134-F4F14C48-FC34-451D-9A7B-465E7E07A46A
author	Ron Milo
title	wds:Q71876134-CE385E9C-1D89-4456-B92E-85EA0607A2B7
title	Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial (en)
page(s)	wds:Q71876134-BB7FC164-A9F0-4143-B8D0-FAFFF7293ED4
page(s)	1457-1462
instance of	wds:Q71876134-3EC13787-6BFA-46B7-B376-4E6517F0B732
instance of	scholarly article
main subject	wds:Q71876134-1CEBD846-9813-4465-8EEC-DC58F957C9B5 wds:Q71876134-85A5B6E1-1C3B-4721-BFFB-DE206B0725A5
main subject	placebo multiple sclerosis
PubMed ID	wds:Q71876134-01EA914F-35D2-47D0-8687-7822C51BD2BA
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8960727
PubMed ID	8960727
published in	wds:Q71876134-AE2CAB00-3A62-4673-80E4-77D37416986D
published in	Neurology
issue	wds:Q71876134-C58BE21A-ED90-4437-A6EC-89C1271412AC
volume	wds:Q71876134-1DF00A1E-9451-4A4E-9D22-C0296DC43F88
issue	6
volume	47
DOI	wds:Q71876134-B3E912CD-EC10-45B2-9FEB-C346A8BD9D2A
DOI	http://dx.doi.org/10.1212/WNL.47.6.1457
DOI	10.1212/WNL.47.6.1457
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71876134
is cites work of	Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Correlation between symptom fatigue and muscular fatigue in multiple sclerosis Management of fatigue in patients with multiple sclerosis Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option? A model for 4-aminopyridine action on K channels: similarities to tetraethylammonium ion action Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy). Immunologically induced electrophysiological dysfunction: implications for inflammatory diseases of the CNS and PNS. A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice 3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study. Aminopyridines for symptomatic treatment in multiple sclerosis Risk factors for and management of cognitive dysfunction in multiple sclerosis Treatment of symptoms in multiple sclerosis Therapy of day time fatigue in patients with multiple sclerosis Neurological channelopathies Treatment of cognitive impairment in multiple sclerosis: position paper Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years. Multiple Sclerosis: Symptomatic Treatment Pharmacologic treatment for memory disorder in multiple sclerosis Pharmacological treatment for memory disorder in multiple sclerosis Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management Critical Appraisal of Evidence for Improving Gait Speed in People with Multiple Sclerosis: Dalfampridine Versus Gait Training Preparation of 3,4-diaminopyridine microparticles by solvent-evaporation methods Symptomatic therapies of multiple sclerosis. [Reconsidering fatigue at the onset of multiple sclerosis] Therapeutic management of cognitive disorders in multiple sclerosis
is cites work of	wds:Q35018491-9824A6F9-808B-44D0-B055-B29B17B7D4A8 wds:Q36474348-B776B7FB-5EA7-4076-8633-D441E347E3DE wds:Q73238614-BD8E5FB0-E146-4B35-8E78-9FE6017EBE24 wds:Q37594075-3207D59C-8622-460D-9F5C-E6A6A41B9091 wds:Q38062861-27324B45-EE54-4D27-8645-F32679733893 wds:Q44100963-55B40E57-98B4-44C6-9505-14BABF7F490B wds:Q77348606-F6E522AF-50E6-4790-A55E-EB8165C8735C wds:Q33770460-8FA0C23E-59EA-405B-87F3-94FD012E3128 wds:Q28178809-1E90E2C8-A1B8-47B1-8960-1B9822D3E802 wds:Q35104451-1418D68E-EE4E-4749-BE9E-2A6F0FE9F1F1 wds:Q41499525-4E19D0E7-4EE1-4EFF-8CD6-842F3FE4A539 wds:Q49722839-5843716E-5C98-4E40-BE5B-653FB074B850 wds:Q33893669-5A279F6D-890C-4439-A7CB-C4442023A7D8

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software